MX382140B - Union de polipeptidos estables al componente 5(c5) de complemento humano. - Google Patents

Union de polipeptidos estables al componente 5(c5) de complemento humano.

Info

Publication number
MX382140B
MX382140B MX2016002397A MX2016002397A MX382140B MX 382140 B MX382140 B MX 382140B MX 2016002397 A MX2016002397 A MX 2016002397A MX 2016002397 A MX2016002397 A MX 2016002397A MX 382140 B MX382140 B MX 382140B
Authority
MX
Mexico
Prior art keywords
sub
binding
complement component
human complement
stable polypeptides
Prior art date
Application number
MX2016002397A
Other languages
English (en)
Spanish (es)
Other versions
MX2016002397A (es
Inventor
Erik Nordling
Joakim Nilsson
Patrik Strömberg
Original Assignee
Swedish Orphan Biovitrum Ab Publ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Swedish Orphan Biovitrum Ab Publ filed Critical Swedish Orphan Biovitrum Ab Publ
Publication of MX2016002397A publication Critical patent/MX2016002397A/es
Publication of MX382140B publication Critical patent/MX382140B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
MX2016002397A 2013-08-28 2014-08-28 Union de polipeptidos estables al componente 5(c5) de complemento humano. MX382140B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1350986 2013-08-28
PCT/EP2014/068282 WO2015028558A1 (en) 2013-08-28 2014-08-28 Stable polypeptides binding to human complement c5

Publications (2)

Publication Number Publication Date
MX2016002397A MX2016002397A (es) 2016-09-08
MX382140B true MX382140B (es) 2025-03-13

Family

ID=51539238

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016002397A MX382140B (es) 2013-08-28 2014-08-28 Union de polipeptidos estables al componente 5(c5) de complemento humano.

Country Status (29)

Country Link
US (1) US9994626B2 (enExample)
EP (2) EP3811961B1 (enExample)
JP (2) JP6767865B2 (enExample)
KR (1) KR102446636B1 (enExample)
CN (1) CN105658228B (enExample)
AU (1) AU2014314222B2 (enExample)
BR (1) BR112016003142A2 (enExample)
CA (1) CA2926976C (enExample)
CY (1) CY1123732T1 (enExample)
DK (1) DK3038633T3 (enExample)
ES (1) ES2842105T3 (enExample)
HR (1) HRP20210013T1 (enExample)
HU (1) HUE052613T2 (enExample)
IL (1) IL244218A (enExample)
LT (1) LT3038633T (enExample)
MX (1) MX382140B (enExample)
MY (1) MY173804A (enExample)
NZ (1) NZ718153A (enExample)
PH (1) PH12016500371A1 (enExample)
PL (1) PL3038633T3 (enExample)
PT (1) PT3038633T (enExample)
RS (1) RS61347B1 (enExample)
RU (2) RU2733897C2 (enExample)
SA (1) SA516370622B1 (enExample)
SG (1) SG11201602679VA (enExample)
SI (1) SI3038633T1 (enExample)
SM (1) SMT202100006T1 (enExample)
UA (1) UA117933C2 (enExample)
WO (1) WO2015028558A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102149028B1 (ko) 2012-02-20 2020-08-27 스위디쉬 오르펀 바이오비트럼 에이비 (피유비엘) 인간 보체 c5에 결합하는 폴리펩티드
HRP20210013T1 (hr) * 2013-08-28 2021-04-02 Ipc Research, Llc Stabilni polipeptidi koji se vezuju za ljudski komplement c5
TR201911279T4 (tr) * 2013-08-28 2019-08-21 Affibody Ab Mutasyona uğramış bir yapı iskelesine sahip polipeptidlerin bağlanması.
UY37651A (es) * 2017-03-31 2018-10-31 Swedish Orphan Biovitrum Ab Publ Polipéptido de unión al il-1r-i
CN111201246B (zh) 2017-07-11 2023-10-27 亚力兄制药公司 结合补体成分c5或血清白蛋白的多肽及其融合蛋白
MX2024005285A (es) * 2021-11-01 2024-09-18 Ipc Res Llc Administracion de proteinas de union a c5.
WO2024227886A1 (en) 2023-05-02 2024-11-07 Mebrahtu Aman Bispecific binding molecule

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
WO2002030985A2 (en) 2000-10-10 2002-04-18 Tanox, Inc. Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection
AT410798B (de) * 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
AU2002331601B2 (en) * 2001-08-17 2006-04-13 Tanox, Inc. Complement pathway inhibitors binding to C5 and C5a without preventing the formation of C5b
ITMI20021527A1 (it) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
WO2005023866A2 (en) 2003-09-10 2005-03-17 Baxter International Inc. Peptides that inhibit complement activation
SE0400274D0 (sv) * 2004-02-09 2004-02-09 Affibody Ab New polypeptide
GB0518443D0 (en) * 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
AU2007223796B2 (en) * 2006-03-08 2013-01-24 Astellas Us Llc Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders
WO2007106585A1 (en) * 2006-03-15 2007-09-20 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
ES2346178T3 (es) 2007-07-31 2015-11-02 Affibody Ab Nuevas composiciones, procedimientos y usos de unión de la albúmina
US9187535B2 (en) 2007-12-19 2015-11-17 Affibody Ab Polypeptide derived from protein A and able to bind PDGF
EP2231860B1 (en) 2007-12-19 2011-10-05 Affibody AB Polypeptide derived from protein a and able to bind pdgf
EP2072525A1 (en) 2007-12-21 2009-06-24 Affibody AB New polypeptides having affinity for HER2
BRPI0916668B1 (pt) 2008-08-05 2021-12-28 Novartis Ag Anticorpo monoclonal isolado, composição farmacêutica, ácido nucleico isolado e vetor
EP2327725A1 (en) 2009-11-26 2011-06-01 InflaRx GmbH Anti-C5a binding moieties with high blocking activity
ES2540114T3 (es) * 2010-07-09 2015-07-08 Affibody Ab Polipéptidos
KR102149028B1 (ko) 2012-02-20 2020-08-27 스위디쉬 오르펀 바이오비트럼 에이비 (피유비엘) 인간 보체 c5에 결합하는 폴리펩티드
JP5980104B2 (ja) 2012-11-22 2016-08-31 三菱電機株式会社 液晶表示装置の製造方法および液晶表示装置の製造システム
US9957330B2 (en) 2012-12-19 2018-05-01 Affibody Ab Polypeptides
TR201911279T4 (tr) * 2013-08-28 2019-08-21 Affibody Ab Mutasyona uğramış bir yapı iskelesine sahip polipeptidlerin bağlanması.
HRP20210013T1 (hr) * 2013-08-28 2021-04-02 Ipc Research, Llc Stabilni polipeptidi koji se vezuju za ljudski komplement c5

Also Published As

Publication number Publication date
RU2016111115A (ru) 2017-10-03
WO2015028558A1 (en) 2015-03-05
JP2020172505A (ja) 2020-10-22
BR122023020080A2 (pt) 2023-12-26
CA2926976A1 (en) 2015-03-05
SI3038633T1 (sl) 2021-05-31
IL244218A0 (en) 2016-04-21
JP2016529270A (ja) 2016-09-23
SMT202100006T1 (it) 2021-03-15
JP6767865B2 (ja) 2020-10-14
CN105658228A (zh) 2016-06-08
HUE052613T2 (hu) 2021-05-28
NZ718153A (en) 2022-05-27
PH12016500371B1 (en) 2016-05-02
RU2020128977A (ru) 2021-11-30
PT3038633T (pt) 2021-01-14
AU2014314222B2 (en) 2018-05-24
BR112016003142A2 (pt) 2017-10-17
RU2733897C2 (ru) 2020-10-09
US20160311870A1 (en) 2016-10-27
CY1123732T1 (el) 2021-10-29
PH12016500371A1 (en) 2016-05-02
ES2842105T3 (es) 2021-07-12
EP3811961A1 (en) 2021-04-28
MX2016002397A (es) 2016-09-08
HK1225656A1 (en) 2017-09-15
LT3038633T (lt) 2021-03-25
EP3038633A1 (en) 2016-07-06
CN105658228B (zh) 2020-02-07
EP3038633B1 (en) 2020-10-14
AU2014314222A1 (en) 2016-04-21
SA516370622B1 (ar) 2018-12-23
RS61347B1 (sr) 2021-02-26
CA2926976C (en) 2023-11-28
HRP20210013T1 (hr) 2021-04-02
RU2016111115A3 (enExample) 2018-04-25
KR20160048121A (ko) 2016-05-03
IL244218A (en) 2017-11-30
DK3038633T3 (da) 2021-01-11
UA117933C2 (uk) 2018-10-25
KR102446636B1 (ko) 2022-09-23
SG11201602679VA (en) 2016-05-30
MY173804A (en) 2020-02-24
EP3811961B1 (en) 2025-08-20
US9994626B2 (en) 2018-06-12
PL3038633T3 (pl) 2021-07-19

Similar Documents

Publication Publication Date Title
MX382140B (es) Union de polipeptidos estables al componente 5(c5) de complemento humano.
MX2021003393A (es) Proteinas de fijacion a sirp alfa y metodos de uso de estas.
EA201591376A1 (ru) Конструкции антител к cdh19 и cd3
BR112015009924A2 (pt) formulações de proteína imunoglobulina de domínio variável duplo estáveis
EA201890337A1 (ru) Конструкции антитела к flt3 и cd3
TR201809571T4 (tr) Ll-22 polipeptidleri ile ıl-22 fc füzyon proteinleri ve kullanım yöntemleri.
MX2018011503A (es) Proteinas de union y metodos de uso de las mismas.
EA201591331A1 (ru) Антагонисты il-33 и их применение
GEP20217326B (en) Constructs having a sirp-alpha domain or variant thereof
EA201690314A1 (ru) Анти-garp-белок и его применения
MX386437B (es) Anticuerpos anti-fap y métodos de utilización.
CL2015002517A1 (es) Proteínas de unión a antígeno.
UA118167C2 (uk) Пептид та його застосування
EA201790934A1 (ru) ВАРИАНТЫ ИНТЕРФЕРОНА α2b
EA201691795A1 (ru) Способ улучшения растворимости белка и пептида за счет использования связывания с фрагментом fc иммуноглобулина
UA110470C2 (ru) Антидот антикоагулянта
TR201902439T4 (tr) Fukoz analogları kullanarak in vivo protein fukosilasyonunun inhibisyon yöntemleri .
UA106900C2 (uk) Агоністичний dr5-зв'язувальний поліпептид
EP3705494A3 (en) Antibodies against frizzled proteins and methods of use thereof
PH12016500101A1 (en) Protease-resistant peptide ligands
NZ732978A (en) Il-17a-binding polypeptides
MX390418B (es) Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso.
CO2020016105A2 (es) Proteínas inmunodominantes y fragmentos en esclerosis múltiple
EA202092508A1 (ru) Составы на основе антител к pd-l1 человека
EA201591609A1 (ru) Варианты альфа-амилазы